HCPCS Level II code J7321 covers single-dose hyaluronan or derivative products (Hyalgan, Supartz, Visco-3) used for intra-articular injections, commonly for osteoarthritis-related joint symptoms. The code is widely used across outpatient settings where viscosupplementation is performed, and it matters nationally because these products represent a non-systemic therapeutic option with specific billing rules and payer coverage variations that affect access and cost of care.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage patterns, billing benchmarks, and clinical context for intra-articular hyaluronan therapy. The summary highlights common sites of service and service type, relevant coding considerations, and where to expect policy variability among major payers.

This publication provides operational guidance on documentation and claim-line composition (without clinical recommendations), summarizes payer coverage themes and exclusions, and outlines typical billing practice for per-dose administration. Data not available in the input is noted where applicable; the report focuses on national implications for practice managers, revenue cycle staff, and clinicians involved in outpatient joint injection services.